|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/06/20 Teladoc Health, Inc. 10-Q 9/30/20 80:9.5M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.37M
2: EX-31.1 Certification -- §302 - SOA'02 HTML 28K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 28K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 24K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 24K
12: R1 Document and Entity Information HTML 76K
13: R2 Consolidated Balance Sheets HTML 110K
14: R3 Consolidated Balance Sheets (Parenthetical) HTML 32K
15: R4 Consolidated Statements of Operations HTML 81K
16: R5 Consolidated Statements of Comprehensive Loss HTML 45K
17: R6 Consolidated Statements of Stockholders' Equity HTML 167K
(Deficit)
18: R7 Consolidated Statements of Cash Flows HTML 121K
19: R8 Organization and Description of Business HTML 26K
20: R9 Basis of Presentation and Principles of HTML 44K
Consolidation
21: R10 Revenue HTML 89K
22: R11 Business Acquisitions HTML 71K
23: R12 Intangible Assets, Net HTML 95K
24: R13 Goodwill HTML 38K
25: R14 Accrued Expenses and Other Current Liabilities HTML 52K
26: R15 Fair Value Measurements HTML 73K
27: R16 Revolving Credit Facility HTML 24K
28: R17 Leasing Operations HTML 33K
29: R18 Convertible Senior Notes HTML 162K
30: R19 Advances from Financing Companies HTML 35K
31: R20 Legal Matters HTML 30K
32: R21 Common Stock and Stockholders' Equity HTML 163K
33: R22 Income Taxes HTML 28K
34: R23 Subsequent Event HTML 25K
35: R24 Basis of Presentation and Principles of HTML 45K
Consolidations (Policies)
36: R25 Revenue (Tables) HTML 78K
37: R26 Business Acquisitions (Tables) HTML 48K
38: R27 Intangible Assets, Net (Tables) HTML 94K
39: R28 Goodwill (Tables) HTML 38K
40: R29 Accrued Expenses and Other Current Liabilities HTML 52K
(Tables)
41: R30 Fair Value Measurements (Tables) HTML 71K
42: R31 Convertible Senior Notes (Tables) HTML 137K
43: R32 Advances from Financing Companies (Tables) HTML 34K
44: R33 Common Stock and Stockholders' Equity (Tables) HTML 157K
45: R34 Basis of Presentation and Principles of HTML 62K
Consolidation - VIE (Details)
46: R35 Basis of Presentation and Principles of HTML 34K
Consolidation - Segment and Foreign Operations
(Details)
47: R36 Revenue - Other Disclosures (Details) HTML 32K
48: R37 Revenue - Disaggregation and Other (Details) HTML 51K
49: R38 Business Acquisitions - Transactions (Details) HTML 79K
50: R39 Business Acquisitions - Assets Acquired, HTML 77K
Liabilities Assumed, Pro forma (Details)
51: R40 Intangible Assets, Net - Summary (Details) HTML 75K
52: R41 Goodwill (Details) HTML 29K
53: R42 Accrued Expenses and Other Current Liabilities HTML 50K
(Details)
54: R43 Fair Value Measurements - Recurring (Details) HTML 50K
55: R44 Fair Value Measurements - Level 3 (Details) HTML 32K
56: R45 Revolving Credit Facility (Details) HTML 25K
57: R46 Leasing Operations - Other (Details) HTML 30K
58: R47 Leasing Operations - Operating Leases (Details) HTML 32K
59: R48 Convertible Senior Notes - Due 2027 - Terms HTML 64K
(Details)
60: R49 Convertible Senior Notes - Due 2027 - Summary HTML 48K
(Details)
61: R50 Convertible Senior Notes - Due 2025 - Terms HTML 65K
(Details)
62: R51 Convertible Senior Notes - Due 2025 - Summary HTML 49K
(Details)
63: R52 Convertible Senior Notes - Due 2022 - Terms HTML 77K
(Details)
64: R53 Convertible Senior Notes - Due 2022 - Summary HTML 49K
(Details)
65: R54 Convertible Senior Notes - Due 2022 - Other HTML 79K
(Details)
66: R55 Advances from Financing Companies (Details) HTML 34K
67: R56 Common Stock and Stockholders' Equity - HTML 23K
Capitalization (Details)
68: R57 Common Stock and Stockholders' Equity - Stock Plan HTML 104K
and Stock Options (Details)
69: R58 Common Stock and Stockholders' Equity - Vesting HTML 28K
(Details)
70: R59 Common Stock and Stockholders' Equity - Fair Value HTML 50K
Assumptions (Details)
71: R60 Common Stock and Stockholders' Equity - Restricted HTML 79K
Stock Units (Details)
72: R61 Common Stock and Stockholders' Equity - HTML 74K
Performance Stock Units (Details)
73: R62 Common Stock and Stockholders' Equity - Employee HTML 44K
Stock Purchase Plan (Details)
74: R63 Common Stock and Stockholders' Equity - HTML 37K
Compensation Costs (Details)
75: R64 Income Taxes (Details) HTML 30K
76: R65 Subsequent Events (Details) HTML 44K
78: XML IDEA XML File -- Filing Summary XML 142K
11: XML XBRL Instance -- tdoc-20200930x10q_htm XML 2.48M
77: EXCEL IDEA Workbook of Financial Reports XLSX 100K
7: EX-101.CAL XBRL Calculations -- tdoc-20200930_cal XML 159K
8: EX-101.DEF XBRL Definitions -- tdoc-20200930_def XML 713K
9: EX-101.LAB XBRL Labels -- tdoc-20200930_lab XML 1.32M
10: EX-101.PRE XBRL Presentations -- tdoc-20200930_pre XML 1.11M
6: EX-101.SCH XBRL Schema -- tdoc-20200930 XSD 177K
79: JSON XBRL Instance as JSON Data -- MetaLinks 349± 543K
80: ZIP XBRL Zipped Folder -- 0001558370-20-013035-xbrl Zip 268K
Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Teladoc Health, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mala Murthy, Chief Financial Officer of the Company, certify, to my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1. | The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: November 6, 2020 |
| |
| | |
| | |
/s/ MALA MURTHY | | |
| | |
Chief Financial Officer | | |
| | |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/6/20 | 4, S-8, S-8 POS | ||
| For Period end: | 9/30/20 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 10/30/20 Teladoc Health, Inc. 8-K:1,2,5,710/29/20 14:301K Toppan Merrill/FA 8/06/20 Teladoc Health, Inc. 8-K:1,9 8/05/20 12:1.3M Toppan Merrill/FA 1/13/20 Teladoc Health, Inc. 8-K:1,3,7,9 1/11/20 13:6.9M Toppan Merrill/FA 2/25/19 Teladoc Health, Inc. 8-K:5,9 2/22/19 2:297K Toppan Merrill/FA 8/10/18 Teladoc Health, Inc. 8-K:5,9 8/10/18 3:277K Toppan Merrill/FA 6/01/18 Teladoc Health, Inc. 8-K:5,9 5/31/18 2:76K Toppan Merrill/FA 5/31/17 Teladoc Health, Inc. 8-K:5,9 5/25/17 4:496K Toppan Merrill/FA |